Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.74−0.06 (-7.79%)
Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%
Allogene Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Allogene Therapeutics's price to book ratio was 0.7× on Nov 11, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.6× to 2.4×, with a median of 1.2×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.7× | −0.3 |
| 2025 | Dec 31, 2025 | 1.0× | +0.0 |
| 2024 | Dec 31, 2024 | 1.0× | +0.0 |
| 2023 | Dec 29, 2023 | 0.9× | −0.3 |
| 2022 | Dec 30, 2022 | 1.2× | −1.0 |
| 2021 | Dec 31, 2021 | 2.2× | −1.0 |
| 2020 | Dec 31, 2020 | 3.2× | −2.0 |
| 2019 | Dec 31, 2019 | 5.1× | – |
See a number that looks wrong?